How it all Began

By Jerry Call
LRG Science Coordinator

Unlike many types of cancer, clinical trials have been an important part of the lives of many GIST patients. This close association began in the summer of 2000. At that time most GIST patients did not even know they had GIST. GIST was considered a subtype of leiomyosarcoma (LMS). At that time leiomyosarcoma (and GIST) was treated with a toxic mix of chemotherapy called MAID. Unfortunately MAID and other types of chemotherapy had little or no effect on GIST.

Word began to arrive in what was at that time the leiomyosarcoma listserv run by ACOR that a new oral drug was working in a phase II trial for GIST. Life Raft Group Executive Director Norman Scherzer was the first to report dramatic results for his wife, Anita. This was quickly followed.

See GIST History on page 2

April 2009 Clinical Trial Update

By Jim Hughes
LRG Clinical Trials Coordinator

United States

Bevacizumab plus Imatinib Phase 3: This trial continues at over 200 regional cancer centers across the United States. Recently added were major GIST trial sites including Fox Chase Cancer Center, Oregon Health & Science University and the University of Chicago. This first line trial is for patients recently diagnosed with unresectable GIST. The trial exclusion criteria include “No prior imatinib mesylate, Bevacizumab, or other agents targeting KIT, vascular endothelial growth factor (VEGF), VEGF receptor, or platelet-derived growth factor receptor (PDGFR) for advanced disease. These agents may have been used in the adjuvant setting provided no recurrence for ≥ 12 months after completion of therapy.” Bevacizumab is an anti-VEGF agent intended to reduce the ability of the tumor to grow new blood vessels. The trial is intended to answer the question of whether the addition of Bevacizumab to Imatinib will lead to longer progression-free survival. Half the patients will receive Bevacizumab, which is administered intravenously once every three weeks. All patients will receive Imatinib.

US and International

Sunitinib or Imatinib Phase 3: New sites have opened in Michigan, Nevada, Ohio, Wisconsin, Germany, the United Kingdom and the Republic of Korea. This trial is for patients having progression while on Imatinib at 400 mg. Patients are randomly assigned to receive either 800 mg Imatinib or 37.5 mg Sunitinib daily.

International

IPI-504 Phase 3: This trial is for patients failing both Imatinib and Sunitinib. It now has multiple new sites in Australia, Belgium, France, Germany, Sweden and the Republic of Korea. IPI-504 is a HSP-90 inhibitor administered intravenously. Patients are randomized to receive either IPI-504 or a placebo.

Nilotinib Versus Imatinib Phase

See Trials Update on page 2
Trials Update from page 1

3: This trial for first line patients is now recruiting at two sites in Canada, and one each in Austria and Spain. In the US 19 sites, 11 states are listed in clinicaltrials.gov along with detailed contact information. All are listed as ‘Not yet recruiting’. That could change quickly.

This phase 3 trial will test whether nilotinib (also known as AMN107 and Tasigna) given as initial treatment for metastatic GIST is better than the current initial therapy, imatinib (Gleevec). Nilotinib is a more powerful inhibitor of KIT and PDGFRA than Gleevec. Lab tests also show it is more effective than imatinib against both wild-type GIST and the exon 13 mutant GIST. Nilotinib also showed higher concentrations levels inside GIST tumor cells in the lab.

Patients entering the trial will be randomized to receive either imatinib or nilotinib. Estimated enrollment for the trial will be 736 patients.

GIST History from page 1

allowed by similar reports from Gary Golnik. Gary’s wife, Mary, was being treated at Dana-Farber Cancer Institute and Gary and Mary met a few other GIST patients in the trial and arranged to keep in touch about side effects and the trial. This group of patients was the very beginning of what we now know as the Life Raft Group.

Word quickly spread on the LMS list that patients with abdominal LMS might instead have GIST and they needed to have their tumors tested for a protein called c-Kit (now usually just called KIT). With no other effective options for GIST, the phase II trial quickly enrolled its allotted number of patients. Interest in the trial was so high that the trial quickly expanded to allow 147 patients and it filled within a few months even though it was only recruiting in 4 sites.

Because of the demand from patients that were finding out about Gleevec thanks to ACOR and the early members of the Life Raft Group, and because of

Inclusion Criteria include:
1. Histologically confirmed diagnosis of GIST which is unresectable and/or metastatic and either:
   - No prior therapy with imatinib or any investigational therapies (e.g. sunitinib). Note: newly diagnosed patients may have received up to 14 days imatinib treatment for disease management while awaiting study start.
   - Recurrent GIST after stopping adjuvant treatment with imatinib and no subsequent treatment with any other investigational therapies (for example sunitinib).
2. At least one measurable site of disease on CT/MRI scan
3. Performance status ≤ 2 (capable of self-care but unable to carry out any work)
4. Normal organ, electrolyte and marrow function

Exclusion Criteria include:
1. Prior treatment with nilotinib or any other drug in this class or other targeted therapy agents with the exception of adjuvant imatinib.
2. Disease progression during adjuvant therapy with imatinib
3. Prior or concomitant malignancy that is currently clinically significant or currently requires active intervention.
4. Impaired cardiac function

Other protocol-defined inclusion/exclusion criteria may apply

The Life Raft Group

Who are we, what do we do?
The Life Raft Group (LRG) directs research to find a cure for a rare cancer and help those affected through support and advocacy until we do. The LRG provides support, information and assistance to patients and families with a rare cancer called Gastrointestinal Stromal Tumor (GIST). The LRG achieves this by providing an online community for patients and caregivers, supporting local in-person meetings, patient education through monthly newsletters and webcasts, one-on-one patient consultations, and most importantly, managing a major research project to find the cure for GIST.

How to help
Donations to The Life Raft Group, a 501(c)(3) nonprofit organization, are tax deductible in the United States. You can donate by credit card at www.liferaftgroup.org/donate.htm or by sending a check to: The Life Raft Group 40 Galesi Dr., Suite 19 Wayne, NJ 07470

Disclaimer
We are patients and caregivers, not doctors. Information shared is not a substitute for discussion with your doctor.
**US Clinical Trials Listing**

### Imatinib + Bevacizumab

**Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor**

**Phase:** 3  
**Conditions:** Gastrointestinal Stromal Tumor  
**Strategy:** Block KIT  
**Block tumor blood vessel growth**  
**NCT #:** NCT00324987  
**Contact:** See each trial site.

- **Geisinger Clinical & Medical Center - CCOP**  
  Danville, PA  
  570-271-6413  
  Albert M. Bernath, MD
- **Montana Cancer Consortium - CCOP**  
  Billings, MT  
  406-238-6290  
  Benjamin Marchello, MD
- **Dayton Clinical Oncology Program - CCOP**  
  Kettering, OH  
  937-395-8678  
  Howard M Gross, MD
- **Toledo Community Hospital Oncology - CCOP**  
  Toledo, OH  
  419-255-5433  
  Paul L. Schafer, MD
- **Columbus - CCOP**  
  Columbus, OH  
  614-443-2267  
  Philip J. Kuebler, MD
- **Gibbs Regional Cancer Center - CCOP**  
  Spartanburg, SC  
  864-560-7050  
  James Bearden, III, MD
- **Southeast Cancer Control Consortium - CCOP**  
  Winston-Salem, NC  
  910-777-3036  
  James M. Atkins, MD

**Ozarks Regional - CCOP**  
Springfield, MO  
417-269-4520  
John W. Goodwin, MD

**Columbia River Oncology Program - CCOP**  
Portland, OR  
503-216-6260  
Keith Larimer, MD

**Carle Cancer Center - CCOP**  
Urbana, IL  
217-383-3394  
Kendrith Rowland, MD

**Metro Minnesota - CCOP**  
St. Louis Park, MN  
592-993-1517  
Patrick J. Flynn, MD

**Kalamazoo - CCOP**  
Kalamazoo, MI  
269-373-7458  
Raymond S. Lord, MD

**Iowa Oncology Research Association - CCOP**  
Des Moines, IA  
515-244-7586  
Roscoe F. Morton, MD

**Wichita - CCOP**  
Wichita, KS  
316-262-4467  
Shaker R. Dakhil, MD

**Oregon Health Sciences University (OHSU)**  
Portland, OR  
503 494-6594  
Michael Heinrich

**University of Chicago**  
Chicago, IL  
Clinical Trials Office, 773-834-7424  
Hedy Kindler, MD

**City of Hope**  
Duarte, CA  
1-866-434-4673  
Warren Chow, MD

### IPI-504

**Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib**

**Phase:** 3  
**Conditions:** Gastrointestinal Stromal Tumor  
**Strategy:** Destroy KIT  
**NCT #:** NCT00688766  
**Contact:** GIST Phase 3 Team  
http://www.ringtrial.com/  
877-504-4634  
RINGtrialinfo@infi.com

- **Dana Farber Cancer Institute**  
  Boston, MA  
  617 632-5117  
tcolon@partners.org  
  George Demetri, MD, PhD
- **Oncology Specialists, Park Ridge**  
  Park Ridge, IL  
  Laura Magid  
  847-410-0667  
lmagid@oncmed.net  
  Pamela Kaiser, MD
- **New Bern Cancer Center**  
  New Bern, NC  
  Jenifer Haggard  
  252-638-0422  
jenifer.haggard@quintiles.com  
  Rick Gorman Jr.M.D.
- **Fox Chase Cancer Center**  
  Philadelphia, PA  
  Jennifer Haggard  
  252-638-0422  
jenifer.haggard@quintiles.com  
  Rick Gorman Jr.M.D.
- **Marshfield Medical Research & Education Foundation**  
  Marshfield, WI  
  715-387-5426  
  Mohammad Q. Khan, MD, FACP
Masitinib, (AB1010)

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumor

Phase: 3
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block KIT
NCT #: NCT00812240
Contact: Antoine Adenis, M.D.
+33 (0)3 20 29 59 59
a-adenis@o-lambret.fr

MD Anderson - Orlando
Orlando, FL
Clinical Trials Office - M.D. Anderson Cancer Center,
713-792-3245
Jon Trent, MD, PhD

Henry Ford Health System
Detroit, MI

Beth Israel Medical Center
New York, NY

Sunitinib or Imatinib

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg)

Phase: 3
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block KIT
NCT #: NCT00372567
Contact: Pfizer Oncology Clinical Trial Information Service
1-877-369-9753
PfizerCancerTrials@emergin gmed.com
1-800-718-1021
1-877-369-9753
PfizerCancerTrials@emergin gmed.com

Evanston Hospital
Evanston, IL
Bruce Brockstein, MD

Glenbrook Hospital
Glencourt, IL
Bruce Brockstein, MD

Highland Park Hospital
Highland Park, IL
Bruce Brockstein, MD

Karmanos Cancer Institute
Detroit, MI
all (800) KARMANOS (1 -800-527-6266) or e-mail info@karmanos.org.
Anthony Sheilds, MD

Siteman Cancer Center, Creve Coeur
Creve Coeur, MO

Washington University
St. Louis, MO

Siteman Cancer Center, St. Peters
St. Peters, MO

New York Presbyterian Hospital - Columbia University Medical Center
New York, NY
Robert Taub, MD

Fox Chase Cancer Center
Philadelphia, PA
1-888-FOX-CHASE
Margaret von Mehren, M.D.
## Nilotinib

### Nilotinib in Advanced GIST

<table>
<thead>
<tr>
<th>Phase:</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions:</td>
<td>Gastrointestinal Stromal Tumor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00782834</td>
</tr>
<tr>
<td>Contact:</td>
<td>FOX CHASE&lt;br&gt;1-888-FOX-CHASE (369) &lt;br&gt;Fox Chase Cancer Center&lt;br&gt;Philadelphia, PA&lt;br&gt;1-888-FOX-CHASE&lt;br&gt;Magaret von Mehren, M.D.</td>
</tr>
</tbody>
</table>

## Sorafenib (Nexavar, BAY 43-9006)

### Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With

<table>
<thead>
<tr>
<th>Phase:</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions:</td>
<td>Gastrointestinal Stromal Tumor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT + Block KIT Signal Path</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00265798</td>
</tr>
<tr>
<td>Contact:</td>
<td>Clinical Trials Office - University of Chicago Cancer Research&lt;br&gt;773-834-7424 &lt;br&gt;University of Chicago&lt;br&gt;Chicago, IL&lt;br&gt;Clinical Trials Office, 773-834-7424&lt;br&gt;Hedy Kindler, MD</td>
</tr>
</tbody>
</table>

## Imatinib + Sunitinib

### Imatinib Mesylate and Sunitinib in Treating Patients With Gastrointestinal Stromal Tumors

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions:</td>
<td>Gastrointestinal Stromal Tumor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00573404</td>
</tr>
<tr>
<td>Contact:</td>
<td>Cancer Information Program&lt;br&gt;800-811-8480 &lt;br&gt;Vanderbilt-Ingram Cancer Center-Cool Springs&lt;br&gt;Franklin, TN&lt;br&gt;615 343-4128&lt;br&gt;Jordan Berlin</td>
</tr>
</tbody>
</table>

---

**BiB021 (CNF2024)**

**An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BiB021 in Subjects With Gastrointestinal Stromal Tumors**

<table>
<thead>
<tr>
<th>Phase:</th>
<th>2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions:</td>
<td>Gastrointestinal Stromal Tumor</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Destroy KIT</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00618319</td>
</tr>
<tr>
<td>Contact:</td>
<td>Biogen Idec&lt;br&gt;<a href="mailto:oncologyclinicaltrials@biogenidec.com">oncologyclinicaltrials@biogenidec.com</a></td>
</tr>
</tbody>
</table>

**Memorial Sloan-Kettering Cancer Center**

New York, NY<br>Robert Maki, MD

**Site name unknown, Rochester**

Rochester, MN

---

**Cancer Care Specialists**

Decatur, IL<br>James Wade III, MD, 217-876-6617<br>jlwade3@sbcglobal.net<br>James Wade III, MD

**USC-Norris Cancer Center**

Los Angeles, CA<br>323-865-3955<br>lenz@hsc.usc.edu<br>Hein-Josef Lenz, M.D

**UC-Davis**

Sacramento, CA<br>916-734-3771<br>David Gandara, MD

**Central Illinois Hem/Onc**

Springfield, IL<br>217-525-2500<br>Edem Agamah, MD

**University of Michigan**

Ann Arbor, MI<br>734-647-8925<br>Scott Schuetze, MD

**Medical College of Wisconsin**

Milwaukee, WI<br>414 805-4603<br>Stuart Wong, MD

---

**Imatinib + Sunitinib**

---

---

---

---

---

---
Dasatinib (BMS-354825)

Trial of Dasatinib in Advanced Sarcomas

Phase: 2
Conditions: Gastrointestinal Stromal Tumor
Strategy: Block KIT + Block KIT Signal Path
NCT #: NCT00464620
Contact: Kathleen Granlund
734-930-7607
kegranlund@sarctrials.org

Arkansas Children's Hospital
Little Rock, AR
Bryce Warren
WarrenBryceA@uams.edu
Kimo Stine

Stanford Cancer Center
Palo Alto, CA
Marti Lohman
650-725-6413
mlohan@stanford.edu

Johns Hopkins Sidney Kimmel Comp Cancer Center
Baltimore, MD
Adult Oncology, 410-955-8804
Pediatric Oncology, 410-955-8751
David Loeb, MD, PhD

Massachusetts General Hospital
Charlestown, MA
Anthony Thomas
617-643-5411
athomas2@partners.org
Edwin Choy, MD

Dana Farber Cancer Institute
Boston, MA
Sarah Solomon
617-582-7503
ssolomon1@partners.org
James Butrynski, MD

University of Michigan
Ann Arbor, MI
Gino Metko
734-647-2095
ginom@med.umich.edu
Scott Schuetze, MD, PhD

Nebraska Methodist Hospital
Omaha, NB
Gladys Pierce
402-354-5129
gladyseirice@nmhs.org
Kirsten Leu, MD

Pennsylvania Oncology
Hematology Associates
Philadelphia, PA
Deb Riordan, RN, BS
215-829-6712
debriordan@pennoncology.com
Arthur Staddon, MD
Fox Chase Cancer Center
Philadelphia, PA
1-888-FOX-CHASE
Margaret von Mehren, M.D.

University of Pittsburgh Cancer Center
Pittsburgh, PA
Lynne Frydrych
412-623-4036
frydrychlm2@upmc.edu
Hussein Tawbi, MD, MSc

MD Anderson Cancer Center
Houston, TX
Joanne Gigstad
715-563-0510
jgigstad@mdanderson.org
Shreyas Patel, MD

Sarcoma Oncology Center
Santa Monica, CA
Viky Chua
(310) 552-9999
vikychua@aol.com
Sant Chawla, MD

University of Iowa Hospitals and Clinics
Iowa City, IA
Melanie Frees, RN
319-356-1228
melanie-frees@uiowa.edu
Mohammed Milhem, MD
**Doxorubicin + Flavopiridol**

*Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery*

**Phase:** 1  
**Conditions:** Gastrointestinal Stromal Tumor  
**Strategy:** Freeze the cell division cycle  
**NCT #:** NCT0098579  
**Contact:** David R. D'Adamo, MD, PhD  
212-639-7573  
dadamod@mskcc.org  
Memorial Sloan-Kettering Cancer Center  
New York, NY  
David D'Adamo, MD, PhD, 212-639-7573.  
David D’Adamo, MD, PhD, 212-639-7573.

---

**SF1126**

*A Phase I Open Label, Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study in SF1126, a PI Kinase (PI3K) Inhibitor in Patients With Solid Tumors That Express KIT*

**Phase:** 1  
**Conditions:** Solid Tumors  
**Strategy:** Block KIT Signal Path  
**NCT #:** NCT0098579  
**Contact:** Joyce Ingold RN MSN OCN  
TGen Clinical Research Services @ SHC  
Debi & Jerry Bisgrove Research Pavilion  
10510 N. 92nd Street, 2nd Floor  
480 323-1339  
ingold@shc.org  
TGen Clinical Research Services  
Scottsdale, AZ  
TGen Clinical Research Services  
Patient Care Coordinator  
10460 N. 92nd Street, Suite 206  
Scottsdale, AZ 85258  
Office 480-323-1339  
Fax 480-323-1339  

**Indiana University Simon Cancer Center**  
Indianapolis, IN  
(317) 278-6942  
gchiorean@iupui.edu  
Elena Chiorean  

**Arizona Cancer Center**  
Tucson, AZ  
(520) 694-CURE(2873)  
Daruka Mahadevan, MD, PhD  

---

**AUY922**

*Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2 Overexpressing Solid Tumors*

**Phase:** 1  
**Conditions:** Solid Tumors  
**Strategy:** Destroy KIT  
**NCT #:** NCT00526045  
**Contact:** Dana Farber Cancer Institute  
Boston, MA  
617 632-5053  
stephen_hodi@dfci.harvard.edu  
Stephen Hodi, MD, PhD  
Washington University  
St. Louis, MO  
800-600-3606 or info@ccadmin.wustl.edu  
Timothy Pluard, MD  
Nevada Cancer Institute  
Las Vegas, NV  
702 822-5433  
nvogelzang@nvcancer.org  
Nicholas Vogelzang, MD  
David Geffen School of Medicine at UCLA  
Los Angeles, CA  
CBritten@mednet.ucla.edu  
Carolyn Britten, M.D.  
Medical College of Georgia  
Augusta, GA  
706-721-2505  
tsamuel@mcat.edu  
Thomas Samuel, M.D.  
Cancer Therapy and Research Center  
San Antonio, TX  
210-562-1797  
mmita@idd.org  
Monica Mita, M.D.  
MD Anderson Cancer Center  
Houston, TX  
Vassiliki Papadimitrakopoulou, MD  
703-792-6363  
vpapadim@mdanderson.org  
Jon Trent, MD, PhD
### BGT226
**A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer**

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT Signal Path</td>
</tr>
<tr>
<td><strong>NCT #:</strong></td>
<td>NCT00600275</td>
</tr>
<tr>
<td><strong>Contact:</strong></td>
<td>Novartis 800 340-6843</td>
</tr>
</tbody>
</table>

**Nevada Cancer Institute**
Las Vegas, NV
Dianna Tercan
(702) 822-5483
Lin-Chi Chen, M.D., Ph.D.

**Dana Farber Cancer Institute**
Boston, MA
Melissa Hohos
617 632-2201
mhohos@partners.org
George Demetri, MD, PhD

**Massachusetts General Hospital**
Charlestown, MA
617-726-6225
nisaac1@partners.org
Stephen Isakoff, MD

**Cancer Therapy and Research Center**
San Antonio, TX
Clinical Studies Referral Office
Telephone: 210-450-5798
Fax: 210-616-5844
E-mail: onctrial@idd.org
Or contact Dr. Francis Giles directly at (210) 450-3838.

### MP470
**MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma**

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions:</td>
<td>Advanced Stage Solid Tumors</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT</td>
</tr>
<tr>
<td><strong>NCT #:</strong></td>
<td>NCT00504205</td>
</tr>
<tr>
<td><strong>Contact:</strong></td>
<td>TGen Clinical Research Services Cancer Care Coordinator 480-323-1255</td>
</tr>
</tbody>
</table>

**South Texas Accelerated Research Therapeutics (START)**
San Antonio, TX
Anthony Tolcher, MD, (210) 593-5255
Note: Contact number is not verified.
Anthony Tolcher, MD

**Virginia Piper Cancer Center**
Scottsdale, AZ
Raoul Tihes, MD, 480-323-1350
Raoul Tihes, MD, 480-323-1350

**TGen Clinical Research Services**
Scottsdale, AZ
TGen Clinical Research Services Patient Care Coordinator 10460 N. 92nd Street, Suite 206
Scottsdale, AZ 85258 Office 480-323-1339 Fax 480-323-1250

### SNX-5422
**SNX-5422 in Treating Patients With Solid Tumor or Lymphoma That Has Not Responded to Treatment**

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Destroy KIT</td>
</tr>
<tr>
<td><strong>NCT #:</strong></td>
<td>NCT00644072</td>
</tr>
<tr>
<td><strong>Contact:</strong></td>
<td>Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937</td>
</tr>
</tbody>
</table>

**Warren Grant Magnuson Clinical Center**
Bethesda, MD
Clinical Trials Office - Warren Grant Magnusen Clinical Center 888-NCI-1937
Giuseppe Giaccone, MD, PhD

### BAY 73-4506
**Phase I study of BAY 73-4506**

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT</td>
</tr>
<tr>
<td><strong>NCT #:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Contact:</strong></td>
<td>Tracy Dufresne, RN, BSN, OCN, CCRP Physician Referral Coordinator 210 593-5265 <a href="mailto:tracy.dufresne@start.stoh.com">tracy.dufresne@start.stoh.com</a></td>
</tr>
</tbody>
</table>

**South Texas Accelerated Research Therapeutics (START)**
San Antonio, TX
Tracy Dufresne, RN, BSN, OCN, CCRP
Physician Referral Coordinator 210 593-5265 tracy.dufresne@start.stoh.com

**MD Anderson Cancer Center**
Houston, TX
Clinical Trials Office - M.D. Anderson Cancer Center, 713-792-3245
Jon Trent, MD, PhD
**BEZ235**

*A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer*

- **Phase:** 1
- **Conditions:** Solid Tumors
- **Strategy:** Block KIT Signal Path
- **NCT #:** NCT00620594
- **Contact:** Novartis
  862-778-8300

- **Nevada Cancer Institute**
  Las Vegas, NV
  Dianna Tercan
  (702) 822-5483
  Wolfram Samlowski, M.D.

- **Sarah Cannon Research Institute**
  Nashville, TN
  615-329-7224
  615-986-4347
  hburriss@tnonc.com
  Howard A. Burris, III MD

**BIIB021 (CNF2024)**

*Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors*

- **Phase:** 1
- **Conditions:** Solid Tumors
- **Strategy:** Destroy KIT
- **NCT #:** NCT00618735
- **Contact:** Biogen Idec
  oncologyclinicaltrials@biogenidec.com

- **South Texas Accelerated Research Therapeutics (START)**
  San Antonio, TX

**GDC-0941**

*An Open-Label, Phase I, Dose-Escalation Study of PI3 Kinase Inhibitor (GDC-0941) in Patients with Locally Advanced or Metastatic*

- **Phase:** 1
- **Conditions:** Solid Tumors
- **Strategy:** Block KIT Signal Path
- **NCT #:**
- **Contact:**

  - **Dana Farber Cancer Institute**
    Boston, MA
    Melissa Hohos
    617 632-2201
    mohos@partners.org
    George Demetri, MD, PhD

  - **TGen Clinical Research Services**
    Scottsdale, AZ
    TGen Clinical Research Services
    Patient Care Coordinator
    10460 N. 92nd Street, Suite 206
    Scottsdale, AZ 85258
    Office 480-323-1339
    Fax 480-323-1750

- **TGen Clinical Research Services**
  Scottsdale, AZ
  Lynne Hull
  480-323-1071
  lhull@shc.org
  Daniel D. Hoff, MD

- **MD Anderson Cancer Center**
  Houston, TX
  Hala Abdulkadir
  713-792-9944
  habdulka@mdanderson.org
  Roy S. Herbst, PhD

**IPI-493**

*A Phase I Dose Escalation Study of IPI-493*

- **Phase:** 1
- **Conditions:** Solid Tumors
- **Strategy:** Destroy KIT
- **NCT #:** NCT00724425
- **Contact:**

  - **Premier Oncology, Scottsdale**
    Scottsdale, AZ
    Patricia Shannon, RN
    480 860-5000
    pshannon@premieroncology.com
    David Mendelson, M.D.

  - **Premier Oncology, Santa Monica**
    Santa Monica, CA
    Marilyn Mulay, NP
    310-633-8400
    mmulay@premieroncology.com
    Lee Rosen M.D.

**PX-478**

*Phase I Trial of PX-478*

- **Phase:** 1
- **Conditions:** Solid Tumors
- **Strategy:** Block related tumor signal paths
  Block tumor blood vessel
- **NCT #:** NCT00522652
- **Contact:**

  - **TGen Clinical Research Services**
    Scottsdale, AZ
    Lynne Hull
    480-323-1071
    lhull@shc.org
    Daniel D. Hoff, MD

**PX-866**

*Phase I Trial of Oral PX-866*

- **Phase:** 1
- **Conditions:** Solid Tumors
- **Strategy:** Block KIT Signal Path
- **NCT #:** NCT00726583
- **Contact:**

  - **University of Colorado**
    Aurora, CO
    Sharon hecker
    720-848-0667
    sharon.hecker@uchsc.edu
    Antonio Jimeno, MD
SNX-5422

Safety and Pharmacology of SNX-5422 Mesylate in Subjects With Refractory Solid Tumor Malignancies

Phase: 1
Conditions: Solid Tumors
Strategy: Destroy KIT
NCT #: NCT00506805
Contact: Pfizer Oncology Clinical Trial Information 1-877-369-9753
PfizerCancerTrials@emergin gmed.com
Pfizer CT.gov Call Center 1-800-718-1021
1-877-369-9753
PfizerCancerTrials@emergin gmed.com

TGen Clinical Research Services
Scottsdale, AZ
Joyce Ingold RN MSN OCN
TGen Clinical Research Services
Patient Care Coordinator
10460 N. 92nd Street, Suite 206
Scottsdale, AZ 85258
Office 480-373-1339
Sarah Cannon Research Institute
Nashville, TN
Jessica Gilbert
615 329-7238
Howard A. Burris, III MD

SNX-5422

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

Phase: 1
Conditions: Solid Tumors
Strategy: Destroy KIT
NCT #: NCT00647764
Contact: Pfizer Oncology Clinical Trial Information Service 1-877-369-9753,
PfizerCancerTrials@emergin gmed.com
Pfizer CT.gov Call Center 1-800-718-1021
1-877-369-9753
PfizerCancerTrials@emergin gmed.com

Site name unknown, Bethesda 20982
Bethesda, MD
Contact: Pfizer Oncology Clinical Trial Information Service 1-877-369-9753
PfizerCancerTrials@emergin gmed.com

Sorafenib + Vorinostat

Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors

Phase: 1
Conditions: Solid Tumors
Strategy: Block KIT + Unblock cell death genes + Destroy KIT
NCT #: NCT00635791
Contact: University of Colorado
Aurora, CO
Stacy Grolnic
720-848-0655
stacy.grolnic@uchsc.edu
David Ross Camidge MD

R1507

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors

Phase: 1
Conditions: Solid Tumors
Strategy: Block related tumor signal paths
NCT #: NCT00560144
Contact: Please reference Study ID Number: PDO_NO21200
973-235-5000 or 800-526-6367 (FOR US ONLY)
973 235-5000
Memorial Sloan-Kettering Cancer Center
New York, NY
212-639-8267
Dr. Tanya Trippett

MD Anderson Cancer Center
Houston, TX
800-392-1611 Patients
800-392-1611 Referring MD
Cynthia E. Herzog
Site name unknown, Denver 80218
Denver, CO
Site name unknown, Bethesda 20982
Bethesda, MD
STA-9090
Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

| Phase: | 1 |
| Conditions: | Solid Tumors |
| Strategy: | Destroy KIT |
| NCT #: | NCT00687934 |
| Contact: | Premier Oncology, Santa Monica |
| | Santa Monica, CA |
| | 310-633-8400 |
| | Lee Rosen |
| | US Oncology - Dayton Oncology & Hematology |
| | Kettering, OH |
| | robert.raju@usoncology.com |
| | (937)293-1622 |
| | Robert Raju |

Sunitinib + CP-751
Phase 1 Study of CP-751, 871 in Combination With Sunitinib in Patients With Advanced Solid Tumors

| Phase: | 1 |
| Conditions: | Solid Tumors |
| Strategy: | Block KIT + Block related tumor signal paths |
| NCT #: | NCT00729833 |
| Contact: | Pfizer CT.gov Call Center EmergingMed |
| | 800 718-1021 |
| | PfizerCancerTrials@emergin gmed.com |
| | Premier Oncology, Santa Monica |
| | Santa Monica, CA |
| | 310 633-8400 |
| | Lee Rosen |
| | South Texas Accelerated Research Therapeutics (START) |
| | San Antonio, TX |

XL765
Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors

| Phase: | 1 |
| Conditions: | Solid Tumors |
| Strategy: | Block related tumor signal paths |
| NCT #: | NCT00485719 |
| Contact: | Exelixis Contact Line |
| | 866-939-4041 |
| | Karmanos Cancer Institute |
| | Detroit, MI |
| | Theresa Laeder 313-576-9386 |
| | Patricia LoRusso, DO |
| | South Texas Accelerated Research Therapeutics (START) |
| | San Antonio, TX |
| | Gina Mangold, MBA 210-413-3594 |
| | gmangold@start.stoh.com |
| | Kyriakos Papadopoulos, MD |

XL147
Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors

| Phase: | 1 |
| Conditions: | Solid Tumors |
| Strategy: | Block KIT Signal Path |
| NCT #: | NCT00486135 |
| Contact: | Exelixis Contact Line |
| | 866-939-4041 |
| | Dana Farber Cancer Institute |
| | Boston, MA |
| | Melisa Hohos, RN, 617-632-2201 |
| | Geoffrey Shapiro, MD, PhD |
| | Karmanos Cancer Institute |
| | Detroit, MI |
| | Dr. Patricia LoRusso 313-576-8716 |
| | Massachusetts General Hospital |
| | Charlestown, MA |
| | Pilar De La Roche Mur 617-632-5841 |
| | Beth Israel Deaconess Medical Center |
| | Boston, MA |
| | Pilar De La Roche Mur 617-632-5841 |
| | Mary Crowley Medical Research Center |
| | Dallas, TX |
| | J.R. Dolan 214-658-1943 |
| | Gerald Edelman MD, PhD |
**International Clinical Trial Update**

---

### Sunitinib

**Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant**

- **Phase:** 4
- **Conditions:** Gastrointestinal Stromal Tumor
- **Strategy:** Block KIT
- **NCT #:** NCT00793871
- **Contact:** Pfizer Oncology Clinical Trial Information Service 1-877-369-9753
  PfizerCancerTrials@emergingmed.com
  Pfizer CT.gov Call Center 1-800-718-1021
  1-877-369-9753

- **Site name unknown Beijing 100035**
  Beijing, China
- **Site name unknown Beijing 100071**
  Beijing, China
- **Site name unknown, Nanjing 210002**
  Nanjing, Jiangsu, JiangsuChina
- **Site name unknown, Beijing 100021**
  Beijing, China

---

### IPI-504

**Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib**

- **Phase:** 3
- **Conditions:** Gastrointestinal Stromal Tumor
- **Strategy:** Destroy KIT
- **NCT #:** NCT00688766
- **Contact:** GIST Phase 3 Team
  http://www.ringtrial.com/
  877-504-4634
  RINGtrialinfo@infi.com

- **Flinders Medical Center**
  Bedford Park, SA, SAAustralia
  Alison Richards
  +08 8204 4830
  Chris Karapetis

- **Ashford Cancer Center**
  Ashford, SA, SAAustralia
  Sara McLaughlin
  +08 8351 0211
  Dusan Kotasek

- **GM HOCA Research Center**
  Auchenflower, Queensland, QueenslandAustralia
  Alice Lau
  +61 7 3737 4572
  Paul Eliadis, MD

- **Cliniques Universitaires Saint Luc**
  Brussels, Belgium
  +0032 2 764 10 37
  Yves Humbert, MD

- **Asan Medical centre**
  Seoul, Republic of Korea
  MoYoul Beck
  +82 2 3010 6110
  Prof. Yoon-Koo Kang

- **Prince of Wales Hospital**
  Randwick, NSW, NSWAustralia
  Daisy Buchanan
  +61 2 9382 2574
  Prof. David Goldstein

---

Peter McCallum Cancer Centre
East Melbourne, VIC, VICAustralia
Jill Davison
+61 3 9656 1111
Grant McArthur, MD

St Augustineus Ziekenhuis
Wilrijk, Brussels, BrusselsBelgium
Hide Haes
+32 (0) 3 443 3759
Luc Dirix, MD

Institut Gustave-Roussy
Villejuif Cedex, France
Rosa Da Silva
+33 (0) 1 42 11 61 73
Axel Le Cesne

St. Herblain
Nantes, France

Helios Klinikum Bad Saarow
Bad Saarow, Germany
Simone Michael
+49 (0) 336 317 3728
Peter Reichardt, MD

Universitatsklinikum Essen, West Germany Cancer Center
Essen, Germany
Edel O’Halloran
+49 (0) 201 723 3147
Sebastian Bauer, MD

Medizinische Hochschule Hannover
Hannover, Germany
Kathleen Schute
+49 (0) 511 352 9196
Victor Grunwald, MD

Universitatsklinikum Mannheim
Mannheim, Germany
Sonja Kogel
+49 (0) 621 383 2042
Peter Hohnberger, MD
Masitinib, (AB1010)

Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour

| Phase: 3 |
| Conditions: Gastrointestinal Stromal Tumor |
| Strategy: Block KIT |
| NCT #: NCT00812240 |
| Contact: Antoine Adenis, M.D. +33 (0)3 20 29 59 59 a-adenis@o-lambret.fr |

Centre Oscar Lambret - Lille
Lille, France
Antoine Adenis, MD

Centre Leon Berard
Lyon, France +33607507064 blay@lyon.fnclcc.fr Jean Yves-Blay, MD, PhD

Centre Georges Francois Leclerc
Dijon, France

Hopital Charles Nicolle
Rouen, France

Centre Hospitalier Victor Josselin
Dreux, France

Centre Rene Huguenin
Saint-Cloud, France

Hopital Jean Minjoz
Besancon, France

Institut Paoli Calmette
Marseilles, France Patrice Viens, MD, PhD

Centre Val d'Aurele
Montpellier, France

Hopital de la Source
Orleans, France

Hopital European Georges Pompidou
Paris, France

Institut Bergonie
Bordeaux, France Binh Bui Nguyen, MD

Hopital Robert Debre
Reims, France

Hopital Saint-Georges
Beirut, Lebanon

Hopital Saint-Joseph
Dora, Lebanon

Middle East Institute of Health
Bsalim, Lebanon

Hamoud Hospital
Saida, Lebanon

American University Hospital Beirut
Lebanon

Sunitinib or Imatinib

Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors (Resistant at 400 mg)

| Phase: 3 |
| Conditions: Gastrointestinal Stromal Tumor |
| Strategy: Block KIT |
| NCT #: NCT00372567 |
| Contact: Pfizer Oncology Clinical Trial Information Service 1-877-369-9753 PfizerCancerTrials@emergin gmed.com 1-800-718-1021 1-877-369-9753 PfizerCancerTrials@emergin gmed.com |

Site name unknown, Hamburg 22767 Hamburg, Germany

Site name unknown, Lai Chi Kok 0 Lai Chi Kok, Kowloon, KowloonHong Kong SAR

Site name unknown, Tuen Mun 0 Tuen Mun, New Territories, New TerritoriesHong Kong SAR

Nilotinib or Imatinib

Phase III, Open-Label Study of Nilotinib Versus Imatinib in GIST Patients

| Phase: 3 |
| Conditions: Gastrointestinal Stromal Tumor |
| Strategy: Block KIT |
| NCT #: NCT00785785 |
| Contact: Novartis Pharmaceuticals +1-800-340-6843 Universitatsklinik f. Innere Medizin Vienna, Austria Thomas Brodowicz, MD |
Dasatinib (BMS-354825)

Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors

| Phase: | 2 |
| Conditions: | Gastrointestinal Stromal Tumor |
| Strategy: | Block KIT + Block KIT Signal Path |
| NCT #: | NCT00568750 |
| Contact: | Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland, CH -1011 41-21-314-0150  Michael Montemurro, MD |

Imatinib

Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor

<p>| Phase: | 2 |
| Conditions: | Gastrointestinal Stromal Tumor |
| Strategy: | Block KIT |
| NCT #: | NCT00764595 |
| Contact: | Tatsuo Kanda, MD Niigata University Medical and Dental Hospital 81-25-227-2228 Niigata University Medical and Dental School Niigata, Japan 81-25-227-2228 Tatsuo Kanda, MD |</p>
<table>
<thead>
<tr>
<th>Study Name</th>
<th>Study Description</th>
<th>Phase</th>
<th>Conditions</th>
<th>Strategy</th>
<th>NCT #</th>
<th>Contact</th>
</tr>
</thead>
</table>
| **Nilotinib** | **Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib** | 2 | Gastrointestinal Stromal Tumor | Block KIT | NCT00718562 | Novartis Japan 81 3 3797 8748 Novartis US 862 778-8330
| | | | | | Site name unknown, Hokkaido, Japan |
| | | | | | Site name unknown, Niigata Niigata, Japan |
| | | | | | Site name unknown, Chiba Chiba, Japan |
| | | | | | Site name unknown, Tokyo Tokyo, Japan |
| | | | | | Site name unknown, Kyushu Kyushu, Japan |
| | | | | | Site name unknown, Aichi Aichi, Japan |
| | | | | | Site name unknown, Osaka Osaka, Japan |
| | | | | | Site name unknown, Shizuoka Shizuoka, Japan |
| **Nilotinib** | **Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or** | 2 | Gastrointestinal Stromal Tumor | Block KIT | NCT00633295 | Novartis Basel 41 61 324 1111
| | | | | | Site name unknown, Tel Aviv Tel Aviv, Israel |
| | | | | | Site name unknown, Tel Hashomer Tel Hashomer, Israel |
| **Nilotinib** | **Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. (OPEN)** | 2 | Gastrointestinal Stromal Tumor | Block KIT | NCT00756509 | + 41 61 324 1111
| | | | | | Site name unknown, Bad Saarow Bad Saarow, Germany |
| **Surgery** | **Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor** | 2 | Gastrointestinal Stromal Tumor | Surgery | NCT00769782 | Tatsuo Kanda, MD Niigata University Medical and Dental Hospital 81-25-227-2228
| | | | | | Niigata University Medical and Dental School Niigata, Japan 81-25-227-2228
| | | | | | Tatsuo Kanda, MD|
| **Radiation** | **Radiation Therapy as Palliative Treatment of GIST (GIST-RT)** | 1 | Gastrointestinal Stromal Tumor | Radiation | NCT00515931 | Heikki Joensuu, M.D., Ph.D. 947173208 Ext. 358 heikki.joensuu@hus.fi
| | | | | | Helsinki University Central Hospital Helsinki, Finland
| | | | | | Heikki Joensuu, M.D., Ph.D. 947173208 Ext. 358 heikki.joensuu, MD
<table>
<thead>
<tr>
<th><strong>Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors</strong></th>
<th><strong>Imatinib + IL-2</strong></th>
<th><strong>AUY922</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase: 4</td>
<td><strong>Imatinib + IL-2</strong></td>
<td>Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2</td>
</tr>
<tr>
<td>Conditions: Gastrointestinal Stromal Tumor</td>
<td>Phase: 1</td>
<td>Phase: 1</td>
</tr>
<tr>
<td>Strategy: Block tumor blood vessel growth</td>
<td>Conditions:</td>
<td>Conditions: Solid Tumors</td>
</tr>
<tr>
<td>NCT #: NCT00777504</td>
<td>NCT #:</td>
<td>NCT #: NCT00526045</td>
</tr>
<tr>
<td>Contact: C.M.L. van Herpen, Md, PhD 31 24 3610353 <a href="mailto:vanherpen@onco.umcn.nl">vanherpen@onco.umcn.nl</a></td>
<td>NCT #:</td>
<td>Contact: 1 800 340-6843</td>
</tr>
<tr>
<td><strong>University Medical Center Nijmegen st Raboud</strong> Nijmegen, Gelderland, Nederland</td>
<td><strong>Institut Gustave-Roussy</strong> Villejuif Cedex, France</td>
<td>Site Name unknown, Bellinzona</td>
</tr>
<tr>
<td>Contact: C.M.L. van Herpen, Md, Phd 31 24 3610353 C.M.L van Herpen, Md, Phd</td>
<td>Dr Patricia Pautier téléphone direct/standard : - / 01 42 11 42 11 courriel : -</td>
<td>Bellinzona, Switzerland</td>
</tr>
<tr>
<td><strong>Everolimus</strong></td>
<td>Institut Gustave-Roussy (IGR) +33 (0)1 42 11 42 10 <a href="mailto:lannes@igr.fr">lannes@igr.fr</a></td>
<td><strong>BGT226</strong></td>
</tr>
<tr>
<td><strong>Treatment of Patients With RAD001 Who Have Progressive Sarcoma</strong></td>
<td><strong>Multi-bacteria vaccine (MBV)</strong></td>
<td><strong>A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer</strong></td>
</tr>
<tr>
<td>Phase: 2</td>
<td><strong>A Phase I Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.</strong></td>
<td>Phase: 1</td>
</tr>
<tr>
<td>Conditions: Sarcoma</td>
<td>Phase: 1</td>
<td>Conditions: Solid Tumors</td>
</tr>
<tr>
<td>Strategy: Block KIT Signal Path</td>
<td>Conditions:</td>
<td>Strategy: Block KIT Signal Path</td>
</tr>
<tr>
<td><strong>Site name unknown, Berlin</strong> Berlin, Germany</td>
<td><strong>Situation unknown,</strong> Frankfurt, Germany</td>
<td><strong>NCT #: NCT00600275</strong></td>
</tr>
<tr>
<td><strong>Site name unknown, Munchen</strong> Munchen, Germany</td>
<td><strong>Situation unknown, Mannheim</strong> Mannheim, Germany</td>
<td>Contact: Novartis 800 340-6843</td>
</tr>
<tr>
<td><strong>Site name unknown, Dusseldorf</strong> Dusseldorf, Germany</td>
<td><strong>Site name unknown, Mannheim</strong> Mannheim, Germany</td>
<td>Hospital Vall d'Hebron Barcelona, Spain</td>
</tr>
<tr>
<td><strong>Site name unknown, Mannheim</strong> Mannheim, Germany</td>
<td><strong>AUY922</strong></td>
<td><strong>Princess Margaret Hospital</strong> Toronto, ON, ONCanada Lillian Siu, M.D.</td>
</tr>
</tbody>
</table>

---

**Everolimus**

**Treatment of Patients With RAD001 Who Have Progressive Sarcoma**

Phase: 2

Conditions: Sarcoma

Strategy: Block KIT Signal Path

NCT #: NCT00767819

Contact: Novartis Basel +41 61 324 1111 Novartis US 862-778-8300

**Site name unknown, Berlin** Berlin, Germany

**Site name unknown, Munchen** Munchen, Germany

**Site name unknown, Dusseldorf** Dusseldorf, Germany

**Site name unknown, Mannheim** Mannheim, Germany

---

**Imatinib + IL-2**

**Imatinib + IL-2**

Phase: 1

Conditions: Gastrointestinal Stromal Tumor

Strategy: Block KIT + Stimulate the immune system

NCT #: Dr Patricia Pautier téléphone direct/standard : - / 01 42 11 42 11 courriel : -

Institut Gustave Roussy (IGR)

+33 (0)1 42 11 42 10 lannes@igr.fr

**Institut Gustave-Roussy** Villejuif Cedex, France

Dr Patricia Pautier téléphone direct/standard : - / 01 Laurence Zitvogel

---

**Multi-bacteria vaccine (MBV)**

**A Phase I Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen.**

Phase: 1

Conditions: Gastrointestinal Stromal Tumor

Strategy: Stimulate the immune system

NCT #: NCT00623831

Contact: Krankenhaus Nordwest Frankfurt, Germany

Antje Neumann 069 7601 4161 neumann.antje@khnw.de

**Krankenhaus Nordwest** Frankfurt, Germany

Elke Jaeger, MD
**XL147**

*Study of the Safety and Pharmacokinetics of XL147 in Adults With Solid Tumors*

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block KIT Signal Path</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00486135</td>
</tr>
<tr>
<td>Contact:</td>
<td>Exelisis Contact Line 866-939-4041</td>
</tr>
</tbody>
</table>
|         | **Hospital Vall d’Hebron**  
|         | Barcelona, Spain  
|         | Gemma Sala  
|         | +34 93 489 4158  
|         | Jose Baselga, MD, PhD |

**XL765**

*Study of the Safety and Pharmacokinetics of XL765 in Adults With Solid Tumors*

<table>
<thead>
<tr>
<th>Phase:</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conditions:</td>
<td>Solid Tumors</td>
</tr>
<tr>
<td>Strategy:</td>
<td>Block related tumor signal paths</td>
</tr>
<tr>
<td>NCT #:</td>
<td>NCT00485719</td>
</tr>
<tr>
<td>Contact:</td>
<td>Exelisis Contact Line 866-939-4041</td>
</tr>
</tbody>
</table>
|         | **Hospital Vall d’Hebron**  
|         | Barcelona, Spain  
|         | Gemma Sala  
|         | +34 93 489 4158  
|         | Jose Baselga, MD, PhD |